Navigation and service

You are here:Rote-Hand-Briefe and Information Letters

Dear Doctor Letter (Rote-Hand-Brief) on Esmya® 5 mg tablets (ulipristal acetate): Restrictions of use, warnings regarding serious liver injury as well as recommendations for monitoring liver function

Date 2018.02.19
Active substance Ulipristal acetate

After reports of serious liver damage, including acute liver failure, in patients treated with Esmya® temporary measures have been taken.